Yonsei Med J.  2016 Mar;57(2):337-341. 10.3349/ymj.2016.57.2.337.

Comparison of Paclitaxel-Coated Balloon Treatment and Plain Old Balloon Angioplasty for De Novo Coronary Lesions

• Her AY
• Ann SH
• Singh GB
• Kim YH
• Yoo SY
• Garg S
• Koo BK
• Shin ES

• KMID: 2374037
• DOI: http://doi.org/10.3349/ymj.2016.57.2.337

Abstract

PURPOSE
This study compared the angiographic outcomes of paclitaxel-coated balloon (PCB) versus plain old balloon angioplasty (POBA) treatment for de novo coronary artery lesions. At present, there is no available data comparing the efficacy of PCB versus POBA for the treatment of de novo coronary lesions.
MATERIALS AND METHODS
This multicenter retrospective observational study enrolled patients with de novo coronary lesions with a reference vessel diameter between 2.5 mm and 3.0 mm and lesion length < or =24 mm who were successfully treated with PCB or POBA. Angiographic measurements and quantitative coronary analysis were performed before and after the procedure, and at 9 months follow-up.
RESULTS
A total of 72 patients (49 receiving PCB and 23 receiving POBA) were enrolled in this study. Late luminal loss was -0.12+/-0.30 mm in the PCB group and 0.25+/-0.50 mm in the POBA group (p<0.001). There was a higher percentage of binary restenosis (diameter stenosis > or =50%) in POBA, compared to PCB (30.4%, n=7 vs. 4.1%, n=2, p<0.001). Target vessel revascularization was higher in the POBA group (13.0%, n=3 vs. 0%, p=0.033).
CONCLUSION
PCB treatment of de novo coronary lesions showed better 9-month angiographic outcomes than POBA treatment alone.

Keyword

Paclitaxel-coated balloon; de novo coronary lesion; plain old balloon angioplasty; restenosis; revascularization

MeSH Terms

Aged
Angioplasty, Balloon, Coronary/*instrumentation/methods
Coronary Angiography
Coronary Artery Disease/therapy
Coronary Stenosis/*therapy
Coronary Vessels/pathology
Female
Follow-Up Studies
Humans
Male
Middle Aged
Paclitaxel/*administration & dosage/therapeutic use
Retrospective Studies
Paclitaxel

Reference

1. Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol. 2007; 49:2145–2150.

2. Agostoni P, Biondi-Zoccai GG, Gasparini GL, Anselmi M, Morando G, Turri M, et al. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J. 2005; 26:881–889.

3. Mintz GS. Remodeling and restenosis: observations from serial intravascular ultrasound studies. Curr Interv Cardiol Rep. 2000; 2:316–325.

4. Vos NS, Dirksen MT, Vink MA, van Nooijen FC, Amoroso G, Herrman JP, et al. Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam (PAPPA): one-year clinical outcome of a pilot study. EuroIntervention. 2014; 10:584–590.

5. Kleber FX, Rittger H, Bonaventura K, Zeymer U, Wöhrle J, Jeger R, et al. Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clin Res Cardiol. 2013; 102:785–797.

6. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006; 47:e1–e121.

7. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol. 2001; 37:2215–2239.

8. Kent KM, Bentivoglio LG, Block PC, Cowley MJ, Dorros G, Gosselin AJ, et al. Percutaneous transluminal coronary angioplasty: report from the Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. 1982; 49:2011–2020.

9. Haude M, Erbel R, Issa H, Meyer J. Quantitative analysis of elastic recoil after balloon angioplasty and after intracoronary implantation of balloon-expandable Palmaz-Schatz stents. J Am Coll Cardiol. 1993; 21:26–34.

10. Rensing BJ, Hermans WR, Strauss BH, Serruys PW. Regional differences in elastic recoil after percutaneous transluminal coronary angioplasty: a quantitative angiographic study. J Am Coll Cardiol. 1991; 17:6 Suppl B. 34B–38B.

11. Liu MW, Roubin GS, King SB 3rd. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation. 1989; 79:1374–1387.

12. Waksman R, Serra A, Loh JP, Malik FT, Torguson R, Stahnke S, et al. Drug-coated balloons for de novo coronary lesions: results from the Valentines II trial. EuroIntervention. 2013; 9:613–619.

13. Kleber FX, Schulz A, Waliszewski M, Hauschild T, Böhm M, Dietz U, et al. Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. Clin Res Cardiol. 2015; 104:217–225.

14. Pires NM, Eefting D, de Vries MR, Quax PH, Jukema JW. Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart. 2007; 93:922–927.

15. Gray WA, Granada JF. Drug-coated balloons for the prevention of vascular restenosis. Circulation. 2010; 121:2672–2680.

16. Axel DI, Kunert W, Göggelmann C, Oberhoff M, Herdeg C, Küttner A, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997; 96:636–645.

17. Scheller B, Speck U, Schmitt A, Böhm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003; 42:1415–1420.